These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 32602545)

  • 1. Prognostic value of immune checkpoint molecules in breast cancer.
    Fang J; Chen F; Liu D; Gu F; Chen Z; Wang Y
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32602545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
    Nishizaki D; Kurzrock R; Miyashita H; Adashek JJ; Lee S; Nikanjam M; Eskander RN; Patel H; Botta GP; Nesline MK; Pabla S; Conroy JM; DePietro P; Sicklick JK; Kato S
    ESMO Open; 2024 Apr; 9(4):102942. PubMed ID: 38503143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Therapeutic Targets of B7 Family in Colorectal Cancer.
    Wang C; Feng H; Cheng X; Liu K; Cai D; Zhao R
    Front Immunol; 2020; 11():681. PubMed ID: 32477326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
    Kitsou M; Ayiomamitis GD; Zaravinos A
    Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
    Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
    Front Immunol; 2020; 11():563044. PubMed ID: 33250890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets.
    Marques RF; Moreno DA; da Silva L; Leal LF; de Paula FE; Santana I; Teixeira G; Saggioro F; Neder L; Junior CA; Mançano B; Reis RM
    Front Immunol; 2023; 14():1062856. PubMed ID: 36825029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
    MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
    J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Gene Expression Profiling Identifies Programmed Cell Death Ligand-1 Centered Immunologic Subtypes of Oral and Squamous Cell Carcinoma With Favorable Survival.
    Yu Y; Tang H; Franceschi D; Mujagond P; Acharya A; Deng Y; Lethaus B; Savkovic V; Zimmerer R; Ziebolz D; Li S; Schmalz G
    Front Med (Lausanne); 2021; 8():759605. PubMed ID: 35127742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix.
    Zong L; Zhang Q; Zhou Y; Kong Y; Yu S; Chen J; Zhang Y; Xiang Y
    J Immunol Res; 2020; 2020():1283632. PubMed ID: 32322590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK Cell-Based Immune Checkpoint Inhibition.
    Khan M; Arooj S; Wang H
    Front Immunol; 2020; 11():167. PubMed ID: 32117298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.
    Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
    Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment.
    Ziogas DC; Theocharopoulos C; Lialios PP; Foteinou D; Koumprentziotis IA; Xynos G; Gogas H
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development.
    Hosseinkhani N; Hemmat N; Baghbani E; Baghbanzadeh A; Kazemi T; Mokhtarzadeh A; Jafarlou M; Amin Doustvandi M; Baradaran B
    Gene; 2024 Feb; 896():148043. PubMed ID: 38042220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
    Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
    Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.
    Pizon M; Schott DS; Pachmann U; Pachmann K
    Int J Oncol; 2018 Nov; 53(5):2289-2299. PubMed ID: 30226585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of inhibitory immune checkpoints and relevant regulatory pathways in breast cancer stem cells.
    Shi H; Yang Y
    Cancer Med; 2021 Jun; 10(11):3794-3807. PubMed ID: 33932112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC).
    von Witzleben A; Fehn A; Grages A; Ezić J; Jeske SS; Puntigam LK; Brunner C; Kraus JM; Kestler HA; Doescher J; Brand M; Theodoraki MN; Ottensmeier CH; Hoffmann TK; Schuler PJ; Laban S
    Int J Cancer; 2021 Apr; 148(8):2023-2035. PubMed ID: 33336372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
    Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
    Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated analysis reveals distinct molecular, clinical, and immunological features of B7-H3 in acute myeloid leukemia.
    Zhang LY; Jin Y; Xia PH; Lin J; Ma JC; Li T; Liu ZQ; Xiang HL; Cheng C; Xu ZJ; Zhou H; Qian J
    Cancer Med; 2021 Nov; 10(21):7831-7846. PubMed ID: 34562306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.